SCHEMBL872233

SCHEMBL872233

CC(=O)Oc1ccc(C=C(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
LMNA P02545 3/20 0.59
KDM4E B2RXH2 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TTR P02766 1/20 0.59
TP53 P04637 1/20 0.59
CYP3A4 P08684 1/20 0.59
PKM P14618 2/20 0.52
POLB P06746 1/20 0.52
TUBB4A P04350 2/20 0.50
TUBB P07437 2/20 0.50
TUBA3C P0DPH7 2/20 0.50
TUBA1B P68363 2/20 0.50
TUBA4A P68366 2/20 0.50
TUBB4B P68371 2/20 0.50
TUBB3 Q13509 2/20 0.50
TUBB2A Q13885 2/20 0.50
TUBB8 Q3ZCM7 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL23152272 0.93 MAPT (0.53) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL10453434 0.84 MAPT (0.56) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL2451780 0.83 MAPT (0.81) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL11354408 0.83 MAPT (0.81) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL10941162 0.83 MAPT (0.81) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL8767998 0.82 ESR1 (0.55) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL8767995 0.82 ESR1 (0.55) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL1100398 0.82 AKR1C3 (0.60) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL1100400 0.82 AKR1C3 (0.60) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL269329 0.82 LMNA (0.80) MAPTMEN1KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023008248-A1 REACTIVE MATERIAL AND THIN FILM PRODUCTION METHOD 株式会社ADEKA 2023-02-02 WO disclosed
WO-2021195361-A2 COMPOSITIONS AND METHODS FOR MODULATING MYOSIN SUBFRAGMENT-2 COILED COIL STABILITY AND METHODS FOR USING THEM UNIVERSITY OF NORTH TEXAS (US) 2021-09-30 WO disclosed
CN-108473484-B Compounds useful as TRPM8 modulators 弗门尼舍公司 2021-06-29 CN disclosed
CN-109310739-A Novel antigens and methods of use thereof 内恩疗法公司 2019-02-05 CN disclosed
US-20170073337-A1 DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2017-03-16 US disclosed
CN-106459960-A Conditionally active biological proteins 生物蛋白有限公司 2017-02-22 CN disclosed
WO-2016191263-A1 THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS TRUSTEES OF DARTMOUTH COLLEGE (US) 2016-12-01 WO disclosed
EP-3094346-A2 VISTA ANTAGONIST AND METHODS OF USE The Trustees Of Dartmouth College (US) 2016-11-23 EP disclosed
EP-3074030-A1 METHOD FOR MITIGATING OR ALLEVIATING SYNAPTIC AND COGNITIVE DEFICITS Trustees of Dartmouth College (US) 2016-10-05 EP disclosed
WO-2015109340-A2 VISTA ANTAGONIST AND METHODS OF USE NOELLE RANDOLPH J (US) 2015-07-23 WO disclosed
CN-101646767-A Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them VERENIUM CORP US 2010-02-10 CN disclosed
EP-1771728-A2 METHODS AND COMPOSITIONS FOR RISK STRATIFICATION The Board of Trustees of The Leland Stanford Junior University (US) 2007-04-11 EP disclosed
EP-1648490-A2 PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY Canbas Co., Ltd. (JP) 2006-04-26 EP disclosed
WO-2006012507-A2 METHODS AND COMPOSITIONS FOR RISK STRATIFICATION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2006-02-02 WO disclosed
WO-2004112820-A2 PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY CANBAS CO., LTD. (JP) 2004-12-29 WO disclosed
WO-1994003601-A9 CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN 1994-03-31 WO disclosed
WO-1994003601-A2 CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN NEW YORK UNIVERSITY (US) 1994-02-17 WO disclosed
US-4933495-A Process for the production of 3-mono or 3,5 dihalogenated 4-acetoxystyrene, its polymerization, and hydrolysis HOECHST CELANESE CORPORATION (US) 1990-06-12 US disclosed
US-4868257-A Process for the production of 3-mono or 3,5 disubstituted-4-acetoxystyrene, its polymerization HOECHST CELANESE CORPORATION (US) 1989-09-19 US disclosed
US-4868256-A Process for the production of 3-mono or 3,5-disubstituted-4-acetoxystyrene its polymerization, and hydrolysis HOECHST CELANESE (US) 1989-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073337-A1 DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP MAPT 198/4885MEN1 3863/4885KMT2A 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.